A Study on the Pursuit of Sustained Clearance of HBsAg in Chronic Hepatitis B(CHB) Patients With Previous Interferon Treatment Using Pegylated Interferon Alpha

Inclusion Criteria: * • Voluntary participation and ability to understand and provide written informed consent. * Age 18-65 years (inclusive), either gender. * Documented HBsAg positivity for at least 6 months, or other evidence confirming chronic hepatitis B (CHB). * Prior interferon therapy before enrollment (treatment discontinuation ≥ 3 months), with HBsAg level at the end of prior treatment reduced by ≥ 50% from baseline. * HBsAg ≤ 500 IU/mL at screening, and HBsAg rebound at screening not exceeding 50% of the baseline HBsAg level during the first-round interferon therapy. * Negative pregnancy test within 24 hours prior to the first dose (for women of childbearing potential); all subjects (male and female) must use effective contraceptive measures during the study. Exclusion Criteria: * • Pregnant or lactating women, or subjects with a pregnancy plan during the study period. * Subjects with neuropsychiatric disorders, in particular a history of depression, anxiety, mania, schizophrenia, or a family history of psychiatric disorders (especially a history of depression or depressive tendency). * Concurrent active infection with hepatitis A, hepatitis C, hepatitis E and/or HIV, or chronic liver disease due to other causes (e.g., alcoholic hepatitis, drug-induced liver injury, autoimmune liver disease, etc.). * Evidence of acute severe liver damage: e.g., ALT \> 10 × ULN, or marked ALT elevation accompanied by significant hyperbilirubinemia. * Evidence …